Hong Kong Stock Movement | JOINN (06127) Rises Over 3% as Company Supports Excyte's Innovative Bispecific Antibody YK012 in Obtaining US FDA IND Approval

JOINN (06127) surged more than 3%, rising 3.6% to HK$19.87 with a trading volume of HK$25.75 million as of press time.

On the news front, according to JOINN's official announcement, Excyte's self-developed innovative bispecific antibody YK012, targeting CD19/CD3, has officially received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of primary membranous nephropathy (pMN). This marks the world's first T-cell engager (TCE) bispecific antibody drug approved for clinical trials targeting this indication, signifying a simultaneous breakthrough for China's original bispecific antibody technology in the autoimmune disease field across both China and the United States.

JOINN, serving as Excyte's non-clinical Contract Research Organization (CRO) partner, comprehensively participated in the YK012 project's pharmacokinetics services, toxicology studies, and other non-clinical trial processes.

According to the introduction, YK012's development leverages Excyte's dual-center strategic layout comprising "Beijing headquarters + U.S. wholly-owned subsidiary Excyte LLC." Following this FDA IND approval, the company will gradually initiate international multi-center clinical research, forming complementary data with the ongoing multi-center trials in China (led by Professor Zhao Minghui from Peking University First Hospital) to accelerate the global development process.